Hologic Inc (Symbol: HOLX) recently traded at $78.23 per share, surpassing the average analyst 12-month target price of $77.33. This milestone indicates a potential reassessment by analysts, who may either downgrade their target or adjust it upward based on the company’s performance. The average target is compiled from 12 analysts, with projections ranging from $70.00 to $90.00 and a standard deviation of $5.63.
Currently, Hologic’s analyst ratings include 5 strong buy, 1 buy, 7 hold, and no sell or strong sell ratings. The average rating is 2.15 on a scale where 1 represents a strong buy and 5 signifies a strong sell.
